Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians

AIDS

Volumn 16, Issue 17, 2002, Pages 2340-2342

  Ifergan, Igal ^a,b   Bernard, Nicole F ^c   Bruneau, Julie ^d   Alary, Michel ^e   Tsoukas, Christos M ^c   Roger, Michel ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P;

ARTICLE; CAUCASIAN; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; EXPOSURE; GENE FREQUENCY; GENETIC POLYMORPHISM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

GENE FREQUENCY; GENES, MDR; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HUMANS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 0037159922     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200211220-00017     Document Type: Article

References (8)

1. MacDonald HR, Bommhardt U, Cerottini JC. Developmentally regulated expression of P-glycoprotein (multidrug resistance) activity in mouse thymocytes. Eur J Immunol 1995, 25:1457-1460.
2. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR-1) gene. J Pharmacol Exp Ther 2001, 297:1137-1143.
3. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
4. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002, 359:30-36.
5. Delph Y. P-glycoprotein: A tangled web waiting to be unraveled. TAG Basic Science Report 2000. http://www.aidsinfonyc.org/tag/science/pgp.html
6. Lee CGL, Ramachandra M, Jeang KT, Martin MA, Pastan I, Gottesman MM. Effect of ABC transporters on HIV-1 infection: Inhibition of virus production by MDR-1 transporter. FASEB J 2000, 14:516-522.
7. Lucia MB, Cauda R, Malorni W, Rainaldi G, Tumbarello M, Tacconelli E, et al. P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. Immunol Lett 1995, 47:223-226.
8. Andreana A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, Gupta S. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type I infection. AIDS Res Hum Retroviruses 1996, 12:1457-1462.